Saturday, February 11, 2017 11:07:33 AM
I own both stocks. OWCP is also concentrating on skin disease applications
of their product lines like VDRM. OWCP share price is a little ahead of VDRM, so pumpers like to use them as a symbol of future price action. But they are 2 different kinds of companies, so comparison is difficult to use in future projections.
VDRM has 1 killer product- Viabecline, which is a topical medicine delivery system. This product is revolutionary with plenty of applications for all skin conditions-monster market. But the company is mysterious. There is very little information on personnel, facilities, sales structures, finances, weak website and Facebook page.
OWCP is probably a bit opposite. The organization structures are solid with plenty of website and 8-k information-the company is basically an open book. Makes it easy to see what type of company it can become. In comparison to VDRM, the product is currently weaker. None of their products have gone through the FDA, unlike Viabecline which full approvals done. Not that OWCP wont get there, just not there now. Their psoriasis product is the only current product that will be available in the near future, but Viabecline has many more markets than that and is ready now.
If there was ever a marriage made in heaven, its these two companies. Each has solutions for each others weaknesses. The two of them together could create a major multi-billion skin disease biopharmaceutical powerhouse. So as a result, links will be made by people between the two. I think the market feels safer with OWCP currently because of the
clearer business organization and process, so the share price has run faster than VDRM. All IMO.
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM